Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.030EUR

Average target price

9.720EUR

Spread / Average Target

+378.82%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP

Market Cap	50.31M 57.28M 46.79M 42.93M 80.67M 5.52B 81.91M 556M 217M 2.71B 215M 210M 9.38B	P/E 2026 *	-2.33x	P/E 2027 *	-2.14x
Enterprise Value	43.01M 48.97M 40M 36.7M 68.96M 4.72B 70.03M 475M 186M 2.32B 184M 180M 8.02B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	55.19%	Yield 2026 *	-	Yield 2027 *	-

07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT
06-09	Pentixapharm to Raise EUR20 Million via Capital Increase	MT
06-09	Pentixapharm Holding AG Announces Positive Feedback From FDA For Initiation Of Phase III PANDA Study With [68Ga]Ga-PentixaFor	CI
05-11	Pentixapharm Holding AG Announces IND Submission To FDA For Phase 3 PANDA Study Of CXCR4-Targeted Cardiovascular Diagnostic	CI

07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ
07-22	Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement	EQ
07-09	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Granting of 8.922.464 Subscription rights	EQ
07-09	Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism	EQ
07-09	Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism	EQ

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news : Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Course Extremes

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

07-22	Pentixapharm Holding AG: Bezugsangebot erfolgreich abgeschlossen, verbleibende Aktien können über Privatplatzierung gezeichnet werden
07-22	Eckert & Ziegler: Bafin prüft wegen Pentixapharm-Abspaltung Bilanz 2024
07-22	Eckert & Ziegler nächster im Bafin-Fokus - Kurs erholt sich
07-22	Bafin prüft Bilanzierung der Pentixapharm-Ausgliederung von Eckert & Ziegler
07-22	Aktien Frankfurt Ausblick: Dax festigt 25.000-Punkte-Marke mit solidem Start

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	57.28M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+161.40%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.79%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+83.13%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+30.00%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+39.80%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.19%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-41.29%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.81%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.43%	161B
Average	+0.44%	+1.33%	+26.20%	+52.36%	404.83B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+78.15%

	2026 *	2027 *
Net sales	-	-
Net income	-21.6M -24.59M -20.09M -18.43M -34.63M -2.37B -35.17M -239M -93.19M -1.16B -92.32M -90.33M -4.03B	-23.5M -26.76M -21.85M -20.05M -37.68M -2.58B -38.26M -260M -101M -1.27B -100M -98.28M -4.38B
Net Debt	-7.3M -8.31M -6.79M -6.23M -11.71M -800M -11.89M -80.62M -31.5M -394M -31.2M -30.53M -1.36B	12.2M 13.89M 11.35M 10.41M 19.56M 1.34B 19.86M 135M 52.64M 658M 52.14M 51.02M 2.27B